Background: The multiple allergen simultaneous test-chemiluminescent assay (MAST-CLA) has been widely used in South Korea to detect allergen-specific immunoglobulin E (IgE). However, MAST-CLA frequently shows concurrent positivity for immune-system cells that fight multiple allergens.Objective: To compare the results of MAST-CLA with those of the new MAST-immunoblot assay, a potential alternative method for concurrently testing for IgE and positivity for multiple allergens.Methods: A total of 55 patients with positive results in MAST-CLA were tested using the MAST-immunoblot system. A total of 133 allergens that displayed discrepancies in MAST-CLA and MAST-immunoblot results were examined with the ImmunoCAP test.Results: The positivity rates for 20 common allergens, as measured by MAST-CLA and MAST-immunoblot, were 53.4% and 19.5%, respectively. The agreement rate of MAST-CLA and ImmunoCAP (75.9%) results was higher than MAST-CLA and MAST-immunoblot (62.4%) results. The mean number of positive results for specific allergens per patient as measured by MASTimmunoblot and MAST-CLA were 5.6 and 15.9, respectively.
Conclusions:The higher agreement rate between ImmunoCAP and MAST-CLA results compared with MAST-CLA and MASTimmunoblot results was caused by frequently occurring concurrent positive reactions to multiple allergens. The frequency of concurrent positive results and the number of allergens showing concurrent positive results was lower in MAST-immunoblot than in MAST-CLA. Therefore, MAST-immunoblot may be helpful in the diagnosis of allergic disease and will decrease any confusion arising from concurrent positivity for multiple allergens.